The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

AACR 2020 | Can we use CH assessment to predict the risk of therapy-related myeloid neoplasms?

May 13, 2020

The AML Hub was pleased to speak to Kelly Bolton, Memorial Sloan Kettering Cancer Center, New York, US, during the American Association of Cancer Research (AACR) virtual meeting, about the use of assessment of clonal hematopoiesis (CH) to predict the risk of therapy-related myeloid neoplasms.

Kelly Bolton reported the results of a study investigating the relationship between CH and oncologic therapy in a large cohort of patients (N = 24,354) with solid tumors and available sequencing data. Then, she talked about CH and therapy-related myeloid neoplasm (tMN) risk and about the use of CH assessment to predict the risk for tMN.

Can we use CH assessment to predict the risk of therapy-related myeloid neoplasms?